The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo muta tion, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an interleukin-6 inhibitor); tocilizumab administration every other week has completely alleviated the patient’s symptoms. Our report further expands the clinical spectrum of patients with TRAPS and reaffirms the use of tocilizumab as a viable alternative treatment option for those patients who are unsatisfactorily responsive to other commonly used biologics, such as canakinumab, anakinra, infliximab, and etanercept. Furthermore, our report may aid in increasing awareness about the existence of mutation-confirmed TRAPS in South Korea in addition to emphasizing the impor tance of actively pursuing genetic testing to correctly diagnose rare AID.
Abstract
Tumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo muta tion, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an interleukin-6 inhibitor); tocilizumab administration every other week has completely alleviated the patient’s symptoms. Our report further expands the clinical spectrum of patients with TRAPS and reaffirms the use of tocilizumab as a viable alternative treatment option for those patients who are unsatisfactorily responsive to other commonly used biologics, such as canakinumab, anakinra, infliximab, and etanercept. Furthermore, our report may aid in increasing awareness about the existence of mutation-confirmed TRAPS in South Korea in addition to emphasizing the impor tance of actively pursuing genetic testing to correctly diagnose rare AID.
참고문헌 (15)
- Deuitch N, "GeneReviews ®" (1993), University of Washington
- McDermott MF, "Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes", Cell, 97, pp.133~144 (1999)
- Cudrici C, "Revisiting TNF receptor-associated periodic syndrome(TRAPS) : current perspectives", Int J Mol Sci, 21, pp.3263~ (2020)
- Yang JA, "Clinical and genetic features of Korean patients with recurrent fever and multisystem inflammation without infectious or autoimmune evidence", J Korean Med Sci, 31, pp.196~201 (2016)
- Jesus AA, "Hereditary autoinflammatory syndromes : a Brazilian multicenter study", J Clin Immunol, 32, pp.922~932 (2012)
- Lobito AA, "Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome(TRAPS)", Blood, 108, pp.1320~1327 (2006)
- Shinar Y, "ISSAID", EMQN best practice guidelines for the genetic diagnosis of monogenic autoinflammatory diseases in the next-generation sequencing era, 2020, pp.66, 525~536
- Ben-Chetrit E, "A patient with periodic fever syndrome : a 20-year delay in diagnosis", Scand J Rheumatol, 38, pp.71~73 (2009)
- Hausmann JS, "The patient journey to diagnosis and treatment of autoinflammatory diseases", Orphanet J Rare Dis, 13, pp.156~ (2018)
- Romano M, "The 2021 EULAR", American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases : cryopyrinassociated periodic syndromes, tumour necrosis factor receptorassociated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist, 2022, pp.81, 907~921
- Koga T, "Interleukin-6 inhibition in the treatment of autoinflammatory diseases", Front Immunol, 13, pp.956795~ (2022)
- Vaitla PM, "Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome : assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab", Arthritis Rheum, 63, pp.1151~1155 (2011)
- La Torre F, "Canakinumab efficacy and long-term tocilizumab administration in tumor necrosis factor receptor-associated periodic syndrome(TRAPS)", Rheumatol Int, 35, pp.1943~1947 (2015)
- Akasbi N, "Successful treatment of tumor necrosis factor receptor-associated periodic syndrome(TRAPS)with tocilizumab : a case report", Eur J Rheumatol, 2, pp.35~36 (2015)
- Hosoya T, "A case presenting with the clinical characteristics of tumor necrosis factor(TNF)receptor-associated periodic syndrome(TRAPS)without TNFRSF1A mutations successfully treated with tocilizumab", Intern Med, 54, pp.2069~2072 (2015)